Renalytix (NASDAQ:RNLX) PT Lowered to $5.00

Renalytix (NASDAQ:RNLXGet Rating) had its price target reduced by BTIG Research from $15.00 to $5.00 in a report published on Friday, The Fly reports. They currently have a buy rating on the stock.

A number of other brokerages have also commented on RNLX. Stifel Nicolaus cut their price target on shares of Renalytix from $17.00 to $7.00 and set a buy rating on the stock in a report on Friday. HC Wainwright lowered their target price on shares of Renalytix from $30.00 to $15.00 and set a buy rating for the company in a research note on Friday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Renalytix from $25.00 to $8.00 in a research note on Friday, April 1st.

Shares of NASDAQ:RNLX opened at $2.56 on Friday. The firm has a market cap of $95.69 million, a PE ratio of -4.06 and a beta of 2.10. The firm’s fifty day moving average is $4.21 and its 200-day moving average is $8.17. Renalytix has a 52 week low of $2.23 and a 52 week high of $34.98.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Philosophy Capital Management LLC increased its stake in Renalytix by 134.6% in the first quarter. Philosophy Capital Management LLC now owns 725,000 shares of the company’s stock valued at $5,017,000 after purchasing an additional 415,958 shares in the last quarter. Pinnacle Associates Ltd. increased its stake in Renalytix by 60.4% in the first quarter. Pinnacle Associates Ltd. now owns 304,844 shares of the company’s stock valued at $2,110,000 after purchasing an additional 114,820 shares in the last quarter. Gofen & Glossberg LLC IL increased its stake in Renalytix by 10.6% in the first quarter. Gofen & Glossberg LLC IL now owns 183,224 shares of the company’s stock valued at $1,268,000 after purchasing an additional 17,500 shares in the last quarter. Slate Path Capital LP bought a new stake in Renalytix in the fourth quarter valued at $2,786,000. Finally, Lazard Asset Management LLC increased its stake in Renalytix by 30.9% in the first quarter. Lazard Asset Management LLC now owns 164,817 shares of the company’s stock valued at $1,140,000 after purchasing an additional 38,892 shares in the last quarter. 16.13% of the stock is owned by hedge funds and other institutional investors.

Renalytix Company Profile (Get Rating)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score.

Recommended Stories

The Fly logo

Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.